
INTEGRITY
NSEPrice History
Investment Checklist
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Trend
Mixed MA signals — sideways/transition
Price Action
Support & Resistance Levels
Volume Analysis
Recent Price Gaps
Stop Loss Levels
Fixed Risk
Technical Levels
Moving Averages
Financials
Peer Comparison
Civil ConstructionPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| LT | Larsen & Toubro Limited | ₹4,049.30 | +4.85% |
| RVNL | Rail Vikas Nigam Limited | ₹233.26 | +4.98% |
| NBCC | NBCC (India) Limited | ₹105.16 | +4.62% |
| KPIL | Kalpataru Projects International Limited | ₹1,301.60 | +3.91% |
| CEMPRO | Cemindia Projects Limited | ₹1,122.40 | -4.50% |
| KEC | KEC International Limited | ₹504.45 | +3.33% |
| ENGINERSIN | Engineers India Limited | ₹234.68 | +4.79% |
| IRCON | Ircon International Limited | ₹135.35 | +3.91% |
| IRB | IRB Infrastructure Developers Limited | ₹20.81 | +2.97% |
| TECHNOE | Techno Electric & Engineering Company Limited | ₹1,038.70 | +2.89% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for INTEGRITY
View AllDabur India says US FDA issues import alert for Silvassa plant drugs
Dabur India said the United States Food and Drug Administration (USFDA) issued Import Alert 66-40 for drugs made at part of its Silvassa facility after an inspection flagged data integrity and maintenance deficiencies.
Dabur India shares in focus after US FDA places drugs from Silvassa plant under import alert. Here’s why
Dabur India shares are set to be in focus after the US FDA issued an import alert on drugs manufactured at its Silvassa plant, citing data integrity lapses. The company said the impact is limited to a small portion of operations, while broader business and domestic sales remain unaffected.
US drug regulator issues import alert for drugs made at a Dabur India plant
The US Food and Drug Administration has placed Dabur India's factory on an import alert. This action follows an inspection that revealed significant issues with data integrity and factory maintenance. Critical manufacturing records were reportedly falsified. Live birds and droppings were also found in a raw material warehouse.